Conference Coverage
Videos
NewsNetwork
OncLive® TV
Peer Exchange
Insights
Attend An Event
State of the Science Summit
Regional Seminar Series
OncLive Global Expo
Giants of Cancer Care
OncLive Community
SPECIALTY TOPICS
CURRENTLY VIEWING
All Specialties
Breast Cancer
Multiple Myeloma
Lung Cancer
Immuno-Oncology News
Gynecologic Oncology
Gastrointestinal Cancer
Colorectal Cancer
Ovarian Cancer
Prostate Cancer
Precision Medicine in Oncology®
Neoadjuvant HER2+
More >>
Related Articles
Multidisciplinary Effort Key to Successful Lung Cancer Screening Programs
New Agents Emerge for Elusive NSCLC Targets
Selective Inhibitors of Rare Mutations Show Encouraging Activity in NSCLC
Related Videos
Dr. Garon on the KEYNOTE-001 Study in NSCLC
Dr. Dumoulin on NVALT 12 Data in NSCLC
Dr. Gainor on Subgroup Analyses From the PACIFIC Trial in NSCLC
News >

Rovalpituzumab Tesirine Active and Safe in Small Cell Lung Cancer

Allie Strickler @Alliejayes
Published: Monday, Feb 13, 2017

Dr. Charles M. Rudin

Charles M. Rudin, MD, PhD

Rovalpituzumab tesirine (Rova-T), a DLL3-targeted antibody-drug conjugate, demonstrated encouraging single-agent antitumor activity with a manageable safety profile in the treatment of patients with recurrent small cell lung cancer (SCLC), according to the results of a phase I study published in The Lancet Oncology.
... to read the full story
To Read the Full Story
REGISTER
LOG IN

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
 
x